Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
Arch Womens Ment Health ; 19(3): 549-52, 2016 06.
Article in English | MEDLINE | ID: mdl-26395260

ABSTRACT

Depression during pregnancy has been associated with an increased risk of adverse outcomes for the infant such as preterm birth. These risks are not reduced with pharmacological treatment, but the effect of non-pharmacological therapies is unknown. We performed a systematic review to assess the risk of adverse perinatal outcomes in non-pharmacologically treated depressed women compared to non-depressed women. We found no studies that met our inclusion criteria, highlighting a critical need for research on this topic.


Subject(s)
Depression/therapy , Pregnancy Complications/therapy , Psychotherapy , Depression/diagnosis , Depression/psychology , Female , Humans , Infant , Infant, Low Birth Weight , Infant, Newborn , Pregnancy , Pregnancy Complications/psychology , Premature Birth/prevention & control , Risk Assessment
2.
Mol Psychiatry ; 21(6): 806-12, 2016 06.
Article in English | MEDLINE | ID: mdl-26122586

ABSTRACT

The pattern of structural brain alterations associated with major depressive disorder (MDD) remains unresolved. This is in part due to small sample sizes of neuroimaging studies resulting in limited statistical power, disease heterogeneity and the complex interactions between clinical characteristics and brain morphology. To address this, we meta-analyzed three-dimensional brain magnetic resonance imaging data from 1728 MDD patients and 7199 controls from 15 research samples worldwide, to identify subcortical brain volumes that robustly discriminate MDD patients from healthy controls. Relative to controls, patients had significantly lower hippocampal volumes (Cohen's d=-0.14, % difference=-1.24). This effect was driven by patients with recurrent MDD (Cohen's d=-0.17, % difference=-1.44), and we detected no differences between first episode patients and controls. Age of onset ⩽21 was associated with a smaller hippocampus (Cohen's d=-0.20, % difference=-1.85) and a trend toward smaller amygdala (Cohen's d=-0.11, % difference=-1.23) and larger lateral ventricles (Cohen's d=0.12, % difference=5.11). Symptom severity at study inclusion was not associated with any regional brain volumes. Sample characteristics such as mean age, proportion of antidepressant users and proportion of remitted patients, and methodological characteristics did not significantly moderate alterations in brain volumes in MDD. Samples with a higher proportion of antipsychotic medication users showed larger caudate volumes in MDD patients compared with controls. This currently largest worldwide effort to identify subcortical brain alterations showed robust smaller hippocampal volumes in MDD patients, moderated by age of onset and first episode versus recurrent episode status.


Subject(s)
Brain/pathology , Depressive Disorder, Major/pathology , Adult , Case-Control Studies , Female , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuroimaging/methods
3.
Eur Psychiatry ; 30(1): 99-105, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25498240

ABSTRACT

PURPOSE: Two common approaches to identify subgroups of patients with bipolar disorder are clustering methodology (mixture analysis) based on the age of onset, and a birth cohort analysis. This study investigates if a birth cohort effect will influence the results of clustering on the age of onset, using a large, international database. METHODS: The database includes 4037 patients with a diagnosis of bipolar I disorder, previously collected at 36 collection sites in 23 countries. Generalized estimating equations (GEE) were used to adjust the data for country median age, and in some models, birth cohort. Model-based clustering (mixture analysis) was then performed on the age of onset data using the residuals. Clinical variables in subgroups were compared. RESULTS: There was a strong birth cohort effect. Without adjusting for the birth cohort, three subgroups were found by clustering. After adjusting for the birth cohort or when considering only those born after 1959, two subgroups were found. With results of either two or three subgroups, the youngest subgroup was more likely to have a family history of mood disorders and a first episode with depressed polarity. However, without adjusting for birth cohort (three subgroups), family history and polarity of the first episode could not be distinguished between the middle and oldest subgroups. CONCLUSION: These results using international data confirm prior findings using single country data, that there are subgroups of bipolar I disorder based on the age of onset, and that there is a birth cohort effect. Including the birth cohort adjustment altered the number and characteristics of subgroups detected when clustering by age of onset. Further investigation is needed to determine if combining both approaches will identify subgroups that are more useful for research.


Subject(s)
Age of Onset , Bipolar Disorder/diagnosis , Adult , Aged , Cluster Analysis , Cohort Studies , Databases, Factual , Female , Global Health , Humans , International Cooperation , Male , Middle Aged , Mood Disorders/epidemiology
4.
Psychol Med ; 44(3): 507-17, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23721695

ABSTRACT

BACKGROUND: Neuroimaging studies have demonstrated an association between lithium (Li) treatment and brain structure in human subjects. A crucial unresolved question is whether this association reflects direct neurochemical effects of Li or indirect effects secondary to treatment or prevention of episodes of bipolar disorder (BD). METHOD: To address this knowledge gap, we compared manually traced hippocampal volumes in 37 BD patients with at least 2 years of Li treatment (Li group), 19 BD patients with <3 months of lifetime Li exposure over 2 years ago (non-Li group) and 50 healthy controls. All BD participants were followed prospectively and had at least 10 years of illness and a minimum of five episodes. We established illness course and long-term treatment response to Li using National Institute of Mental Health (NIMH) life charts. RESULTS: The non-Li group had smaller hippocampal volumes than the controls or the Li group (F 2,102 = 4.97, p = 0.009). However, the time spent in a mood episode on the current mood stabilizer was more than three times longer in the Li than in the non-Li group (t(51) = 2.00, p = 0.05). Even Li-treated patients with BD episodes while on Li had hippocampal volumes comparable to healthy controls and significantly larger than non-Li patients (t(43) = 2.62, corrected p = 0.02). CONCLUSIONS: Our findings support the neuroprotective effects of Li. The association between Li treatment and hippocampal volume seems to be independent of long-term treatment response and occurred even in subjects with episodes of BD while on Li. Consequently, these effects of Li on brain structure may generalize to patients with neuropsychiatric illnesses other than BD.


Subject(s)
Antimanic Agents/pharmacology , Bipolar Disorder/drug therapy , Hippocampus/drug effects , Lithium Compounds/pharmacology , Neuroprotective Agents/pharmacology , Adult , Analysis of Variance , Antimanic Agents/therapeutic use , Bipolar Disorder/pathology , Case-Control Studies , Diagnostic and Statistical Manual of Mental Disorders , Female , Hippocampus/pathology , Humans , Image Processing, Computer-Assisted/methods , Interview, Psychological , Lithium Compounds/therapeutic use , Magnetic Resonance Imaging/methods , Male , Neuroprotective Agents/therapeutic use , Prospective Studies , Recurrence , Time Factors , Treatment Outcome
5.
Acta Psychiatr Scand ; 129(3): 193-201, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23662597

ABSTRACT

OBJECTIVE: Key questions remain unaddressed concerning the nature of interpersonal functioning in trauma survivors, including the ability to understand and interpret other people's thoughts and feelings. Here, we investigate theory of mind (ToM) performance of women with PTSD related to childhood abuse in comparison to healthy controls. METHOD: Participants completed two ToM tasks, the Interpersonal Perception Task-15 (IPT-15) and the Reading the Mind in the Eyes Task - Revised (RMET). RESULTS: Relative to controls, women with a history of childhood trauma had difficulty recognizing familial relationships depicted in the IPT-15 (P = 0.005). No other category of the IPT-15 showed significant group differences. In addition, while healthy women displayed faster RMET reaction times to emotionally valenced mental states (positive: P = 0.003; negative: P = 0.016) compared with neutral mental states, the PTSD group showed similar reaction times across all valences. The presence of dissociative symptoms (e.g., disengagement, amnesia, identity dissociation) was strongly associated with hindered accuracy of complex mental state identification and altered perception of kinship interactions. CONCLUSION: Women with PTSD stemming from childhood trauma show changes in ToM abilities particularly those often involved in the interpretation of family interactions. In addition, individuals with PTSD showed slower reaction times during the recognition of complex mental states from emotionally salient facial/eye expressions in comparison with healthy subjects.


Subject(s)
Child Abuse/psychology , Interpersonal Relations , Social Perception , Stress Disorders, Post-Traumatic/physiopathology , Theory of Mind/physiology , Adult , Child , Female , Humans , Middle Aged , Stress Disorders, Post-Traumatic/etiology
6.
Mol Psychiatry ; 16(3): 252-64, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20661246

ABSTRACT

Major depressive disorder (MDD) has until recently been conceptualized as an episodic disorder associated with 'chemical imbalances' but no permanent brain changes. Evidence has emerged in the past decade that MDD is associated with small hippocampal volumes. This paper reviews the clinical and biological correlates of small hippocampal volumes based on literature searches of PubMed and EMBASE and discusses the ways in which these data force a re-conceptualization of MDD. Preclinical data describe the molecular and cellular effects of chronic stress and antidepressant treatment on the hippocampus, providing plausible mechanisms through which MDD might be associated with small hippocampal volumes. Small hippocampal volumes are associated with poor clinical outcome and may be a mechanism through which MDD appears to be a risk factor for Alzheimer's disease. The pathways through which stress may be linked to MDD, the emergence of chronicity or treatment resistance in MDD and the association between MDD and memory problems may be at least partially understood by dissecting the association with depression and changes in the hippocampus. MDD must be re-conceived as a complex illness, associated with persistent morphological brain changes that are detectable before illness onset and which may be modified by clinical and treatment variables.


Subject(s)
Biomedical Research , Depressive Disorder, Major/pathology , Hippocampus/physiopathology , Psychiatry , Animals , Databases, Factual/statistics & numerical data , Hippocampus/pathology , Humans
7.
Neuroscience ; 171(3): 734-46, 2010 Dec 15.
Article in English | MEDLINE | ID: mdl-20816924

ABSTRACT

An immunogenic challenge during early postnatal development leads to long-term changes in behavioural and physiological measures reflecting enhanced emotionality and anxiety. Altered CNS serotonin (5-HT) signalling during the third postnatal week is thought to modify the developing neurocircuitry governing anxiety-like behaviour. Changes in 5-HT signalling during this time window may underlie increased emotionality reported in early immune challenge rodents. Here we examine both the spatial and temporal profile of 5-HT related gene expression, including 5HT1A, 2A, 2C receptors, the 5-HT transporter (5HTT), and tryptophan hydroxylase 2 (TPH2) during early development (postnatal day [P]14, P17, P21, P28) in mice challenged with lipopolysaccharide (LPS) during the first postnatal week. Expression levels were measured using in situ hybridization in regions associated with mediating emotive behaviours: the dorsal raphe (DR), hippocampus, amygdala, and prefrontal cortex (PFC). Increased TPH2 and 5HTT expression in the ventrolateral region of the DR of LPS-mice accompanied decreased expression of ventral DR 5HT1A and dorsal DR 5HTT. In the forebrain, 5HT1A and 2A receptors were increased, whereas 5HT2C receptors were decreased in the hippocampus. Decreased mRNA expression of 5HT2C was detected in the amygdala and PFC of LPS-treated pups; 5HT1A was increased in the PFC. The majority of these changes were restricted to P14-21. These transient changes in 5-HT expression coincide with the critical time window in which 5-HT disturbance leads to permanent modification of anxiety-related behaviours. This suggests that alterations in CNS 5-HT during development may underlie the enhanced emotionality associated with an early immune challenge.


Subject(s)
Brain Chemistry/genetics , Brain Chemistry/immunology , Gene Expression Regulation, Developmental/immunology , Receptors, Serotonin/deficiency , Serotonin/genetics , Animals , Animals, Newborn , Female , Limbic System/immunology , Limbic System/metabolism , Male , Mesencephalon/immunology , Mesencephalon/metabolism , Mice , RNA Editing/genetics , RNA Editing/immunology , Receptors, Serotonin/biosynthesis , Receptors, Serotonin/genetics , Serotonin/biosynthesis , Serotonin/metabolism
8.
Obes Rev ; 8(5): 409-18, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17716298

ABSTRACT

Metabolic syndrome which includes visceral obesity, elevated triglycerides, elevated fasting blood sugar, high blood pressure and a decrease in high-density lipoprotein cholesterol levels comprises the most common chronic physical illnesses in modern society. Components of the metabolic syndrome play a role in the pathogenesis of a plethora of medical illnesses. Evidence has emerged highlighting the detrimental effects of metabolic syndrome and its constituent features on the cognitive aspects of neurological function. The precise mechanisms underlying this association are not known but a combination of neuroanatomical changes and neuroendocrine consequences of somatic dysregulation may be relevant. As the population ages and the prevalence of metabolic syndrome increases, it is important that this clinically relevant association be recognized.


Subject(s)
Cognition Disorders/etiology , Metabolic Syndrome/complications , Obesity/complications , Blood Glucose/metabolism , Cognition Disorders/epidemiology , Cognition Disorders/pathology , Humans , Metabolic Syndrome/epidemiology , Metabolic Syndrome/pathology , Prevalence , Risk Factors
10.
Acta Psychiatr Scand ; 112(2): 105-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15992391

ABSTRACT

OBJECTIVE: To examine the risk of relapse into mania or depression with varying duration of antidepressant treatment in a cohort of 59 patients with bipolar disorder. METHOD: An open naturalistic evaluation using life charting methods of patients with 1 year follow-up, who responded to antidepressant treatment and who then less or more than 6 months of antidepressant treatment. RESULTS: Patients who received more than 6 months of antidepressant treatment were less likely to relapse into depression at follow-up of 1 year. There was no difference in relapse rates for mania in the different antidepressant treatment duration groups. Gender and bipolar subtype did not significantly affect relapse rates for depression or mania. CONCLUSION: Our data, taken with other studies, suggest that the duration of optimal antidepressant treatment in bipolar disorder must be further evaluated.


Subject(s)
Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Adult , Aged , Bipolar Disorder/psychology , Cohort Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Secondary Prevention , Survival Analysis , Time Factors , Treatment Outcome
11.
Mol Psychiatry ; 10(9): 811-26, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15970930

ABSTRACT

The search for susceptibility genes for bipolar disorder (BD) depends on appropriate definitions of the phenotype. In this paper, we review data on diagnosis and clinical features of BD that could be used in genetic studies to better characterize patients or to define homogeneous subgroups. Clinical symptoms, long-term course, comorbid conditions, and response to prophylactic treatment may define groups associated with more or less specific loci. One such group is characterized by symptoms of psychosis and linkage to 13q and 22q. A second group includes mainly bipolar II patients with comorbid panic disorder, rapid mood switching, and evidence of chromosome 18 linkage. A third group comprises typical BD with an episodic course and favourable response to lithium prophylaxis. Reproducibility of cognitive deficits across studies raises the possibility of using cognitive profiles as endophenotypes of BD, with deficits in verbal explicit memory and executive function commonly reported. Brain imaging provides a more ambiguous data set consistent with heterogeneity of the illness.


Subject(s)
Bipolar Disorder/genetics , Bipolar Disorder/epidemiology , Chromosome Mapping , Chromosomes, Human, Pair 17 , Cognition , Comorbidity , Humans , Phenotype , Prevalence , Psychotic Disorders/genetics
12.
J Clin Endocrinol Metab ; 88(10): 4551-5, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14557420

ABSTRACT

Some hypothyroid patients receiving levothyroxine replacement therapy complain of depressive symptoms despite normal TSH measurements. It is not known whether adding T(3) can reverse such symptoms. We randomized 40 individuals with depressive symptoms who were taking a stable dose of levothyroxine for treatment of hypothyroidism (excluding those who underwent thyroidectomy or radioactive iodine ablation of the thyroid) to receive T(4) plus placebo or the combination of T(4) plus T(3) in a double-blind manner for 15 wk. Participants receiving combination therapy had their prestudy dose of T(4) dropped by 50%, and T(3) was started at a dose of 12.5 micro g, twice daily. T(4) and T(3) doses were adjusted to keep goal TSH concentrations within the normal range. Compared with the group taking T(4) alone, the group taking both T(4) plus T(3) did not report any improvement in self-rated mood and well-being scores that included all subscales of the Symptom Check-List-90, the Comprehensive Epidemiological Screen for Depression, and the Multiple Outcome Study (P > 0.05 for all indexes). In conclusion, the current data do not support the routine use of combined T(3) and T(4) therapy in hypothyroid patients with depressive symptoms.


Subject(s)
Depression/drug therapy , Hypothyroidism/drug therapy , Thyroxine/administration & dosage , Triiodothyronine/administration & dosage , Adult , Affect/drug effects , Depression/etiology , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hypothyroidism/complications , Hypothyroidism/psychology , Male , Middle Aged , Thyroid Gland/drug effects , Thyroid Gland/physiology , Thyroxine/blood , Treatment Outcome , Triiodothyronine/blood
13.
Psychol Med ; 33(1): 121-9, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12537043

ABSTRACT

BACKGROUND: Numerous studies have suggested, via the interpretation of negative priming effects, that subjects with schizophrenia are less able than controls to inhibit irrelevant distracting information. Further issues concerning impairment in inhibitory processes are investigated here. First, recent research has revealed that negative priming (NP) effects can be caused by different processes, distractor inhibition or perceptual review. Therefore, conclusions concerning reduced inhibition in patients with schizophrenia are not possible from previous NP research. Secondly, previous NP studies have required subjects to identify some feature of the target. This is the first study to examine NP that uses a spatial task in patients with schizophrenia. METHOD: Twenty-eight subjects with schizophrenia and 28 age and sex matched non-psychiatric control subjects completed a computerized NP task that eliminated the possible contribution of perceptual review. RESULTS: Subjects with schizophrenia had reduced levels of NP compared to control subjects on this spatial NP task (t = 2.46, P < 0.02). Current age, positive, negative or total PANNS scores did not correlate with negative priming scores, but post hoc analyses revealed that clozapine-treated patients had significantly greater levels of negative priming than patients receiving typical antipsychotic medications. CONCLUSIONS: The present experiment eliminated the contribution of perceptual review to negative priming and demonstrated that when a pure measure of inhibition is taken on a localization task, patients with schizophrenia were less able to inhibit irrelevant distracting stimuli. The fact that NP was reduced in a spatial task suggested a more diffuse reduction in inhibition than previous studies that examined only identification-based responses.


Subject(s)
Attention , Inhibition, Psychological , Psychomotor Performance , Schizophrenia/diagnosis , Schizophrenic Psychology , Adult , Antipsychotic Agents/adverse effects , Attention/drug effects , Case-Control Studies , Female , Humans , Male , Psychiatric Status Rating Scales , Psychomotor Performance/drug effects , Reaction Time , Schizophrenia/drug therapy , Severity of Illness Index
14.
Acta Psychiatr Scand ; 105(6): 427-30, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12059846

ABSTRACT

OBJECTIVE: To assess the effect of different antidepressants on induction of mania and cycle acceleration, commonly accepted unwanted effects of antidepressant treatment for acute bipolar depression. There is, however, the suggestion that certain classes of antidepressants may be less likely than others to cause these unwanted effects. METHOD: We conducted a prospective, open, naturalistic, life charting study to assess the occurrence of onset of mania and cycle acceleration attributable to two antidepressant classes: selective serotonin reuptake inhibitors (SSRIs) and bupropion. RESULTS: No difference was found between the two drug classes for either antidepressant-induced mania or cycle acceleration. Antidepressant-induced mania was much more likely to occur in bipolar I rather than bipolar II patients. The overall occurrence of induction of mania and cycle acceleration was low across antidepressant classes. CONCLUSION: These findings suggest that there is probably no difference in the risk of antidepressant-induced mania or cycle acceleration across commonly used classes of antidepressants for the treatment of bipolar depression.


Subject(s)
Antidepressive Agents/classification , Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/epidemiology , Periodicity , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged
15.
Psychol Med ; 32(2): 251-8, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11866320

ABSTRACT

BACKGROUND: Neuropsychological studies have suggested that memory systems reliant on medial temporal lobe structures are impaired in patients with depression. There is less data regarding whether this impairment is specific to recollection memory systems, and whether clinical features predict impairment. This study sought to address these issues. METHOD: A computerized process-dissociation memory task was utilized to dissociate recollection and habit memory in 40 patients with past or current major depression and 40 age, sex and IQ matched non-psychiatric control subjects. The Cognitive Failures Questionnaire was used to assess patients' perceptions of day-to-day memory failures. RESULTS: Patients had impaired recollection memory (t = 4.7, P < 0.001), but no impairment in habit memory when compared to controls. Recollection memory performance was not predicted by indices of current mood state, but was predicted by self-assessments of impairment (beta = -0.33; P = 0.008) and past number of depressions (beta = -0.41; P = 0.001). There was no evidence that standard therapy with antidepressant medication either improved or worsened memory performance. CONCLUSIONS: The results confirm that patients with multiple past depressions have reduced function on recollection memory tasks, but not on habit memory performance. The memory deficits were independent of current mood state but related to past course of illness and significant enough that patients detected impairment in day-to-day memory function.


Subject(s)
Affect , Depressive Disorder, Major/psychology , Mental Recall , Neuropsychological Tests , Adult , Affect/physiology , Antidepressive Agents/therapeutic use , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/physiopathology , Female , Humans , Male , Mental Recall/physiology , Middle Aged , Paired-Associate Learning/physiology , Recurrence , Retention, Psychology/physiology , Temporal Lobe/physiopathology
16.
Behav Neurosci ; 115(5): 1145-53, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11584927

ABSTRACT

Evidence suggests that brain-derived neurotrophic factor (BDNF) may be important in the pathophysiology of depression, in addition to its role as a neurotrophic factor for sensory neurons. The authors conducted a series of experiments examining the behavioral profile of BDNF heterozygous knockout and wild-type mice. The heterozygous and wild-type mice did not differ on measures of activity, exploration, or hedonic sensitivity, or in the forced swim test. When assessed in the learned helplessness paradigm, heterozygous mice were slower to escape after training than were wild-type mice (p = .02). This effect may be accounted for by the fact that these mice demonstrate a reduced sensitivity to centrally mediated pain, apparent on the hot plate and Formalin injection tests of nociception. Overall, heterozygous mice were not more likely to display anxious or depressive-like behaviors and, consequently, may not constitute a murine model of genetic vulnerability to mood and anxiety disorders.


Subject(s)
Affect/physiology , Arousal/genetics , Motivation , Pain Threshold/physiology , Animals , Arousal/physiology , Avoidance Learning/physiology , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/physiology , Escape Reaction/physiology , Exploratory Behavior/physiology , Female , Helplessness, Learned , Heterozygote , Male , Mice , Mice, Knockout
17.
Psychol Med ; 31(7): 1269-77, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11681553

ABSTRACT

BACKGROUND: Several studies have suggested that visual backward masking (VBM) impairment is present in patients with bipolar disorder, but the clinical features, such as current symptoms, treatment status and past burden of illness that may contribute to the impairment have not been well described. This study examined well-characterized euthymic patients on two VBM tasks to ascertain the extent of VBM impairment in this group and the clinical correlates of this impairment. METHOD: Twenty-eight euthymic patients with a DSM-IV diagnosis of bipolar disorder were matched by age, sex and IQ with 28 non-psychiatric control subjects. Both groups completed two VBM tasks; one required subjects to locate the target stimulus, one required identification of the target stimulus. Reaction times and error rates across a range of target-mask inter-stimulus intervals were assessed. RESULTS: Patients were significantly slower and had more errors on both VBM tasks. There was a significant relation between reaction times on the identification task and past burden of illness, particularly past number of depressions. There was no discernible impact of treatment status on reaction time or performance, including no difference in lithium-treated versus not treated subjects. CONCLUSIONS: These results are consistent with previous reports of neuropsychological deficits in euthymic bipolar disorder patients. The potential benefit to employing tasks such as VBM is that it may provide a method for relating clinical variables such as illness burden with known neural pathways in order to elucidate better the pathophysiology leading to impaired cognitive performance in patients with bipolar disorder.


Subject(s)
Bipolar Disorder/rehabilitation , Perceptual Masking , Visual Perception , Adult , Ambulatory Care , Female , Humans , Male , Task Performance and Analysis
18.
Brain Res Bull ; 55(5): 625-9, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11576759

ABSTRACT

There is an established relationship between the monoaminergic neurotransmitter system and mood disorders. In an attempt to define further the pathophysiology of mood disorders, research is focussing on intracellular second messenger systems, including cyclic adenosine 3',5'-monophosphate (cAMP) and the polyphosphoinositol generated second messengers. The availability of tissue from the Stanley Foundation Neuropathology Consortium has offered us the opportunity to make a number of observations with respect to these second messenger systems in tissue from patients with major depressive disorder and bipolar affective disorder. There is evidence that antidepressants stimulate components of the cAMP pathway in patients with depression while mood stabilizers blunt the same pathway in patients with bipolar disorder. Furthermore, downstream targets of this pathway appear to be altered in patients with mood disorders. The relations between changes in second messenger systems, gene transcription, and clinical effects of current therapeutic regimens has implications for development of novel treatments of mood disorders.


Subject(s)
Bipolar Disorder/metabolism , Cerebral Cortex/metabolism , Cyclic AMP/metabolism , Depressive Disorder, Major/metabolism , Neurons/metabolism , Signal Transduction/physiology , Adenylyl Cyclases/drug effects , Adenylyl Cyclases/metabolism , Antidepressive Agents/pharmacology , Archives , Bipolar Disorder/pathology , Bipolar Disorder/physiopathology , Calcium-Calmodulin-Dependent Protein Kinases/drug effects , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Cyclic AMP Response Element-Binding Protein/drug effects , Cyclic AMP Response Element-Binding Protein/metabolism , Depressive Disorder, Major/pathology , Depressive Disorder, Major/physiopathology , GTP-Binding Proteins/drug effects , GTP-Binding Proteins/metabolism , Humans , Immunoblotting , Lithium/pharmacology , Neurons/pathology , Signal Transduction/drug effects , Tissue Banks
19.
Biol Psychiatry ; 50(4): 260-5, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11522260

ABSTRACT

BACKGROUND: The cAMP signaling pathway, and its downstream neurotrophic factor BDNF, are major targets of antidepressant medications. Abnormalities in this pathway have previously been reported in postmortem brain of subjects with mood disorders. This study was designed to test whether the diagnosis of a mood disorder, or treatment with an antidepressant or mood stabilizer was associated with changes in hippocampal BDNF in postmortem brain. METHODS: Frozen postmortem anterior hippocampus sections were obtained from the Stanley Foundation Neuropathology Consortium. Tissue from subjects with major depression, bipolar disorder, schizophrenia and nonpsychiatric control subjects were stained for BDNF using immunohistochemistry. RESULTS: Increased BDNF expression was found in dentate gyrus, hilus and supragranular regions in subjects treated with antidepressant medications at the time of death, compared with antidepressant-untreated subjects. Furthermore, there was a trend toward increased BDNF expression in hilar and supragranular regions in depressed subjects treated with antidepressants, compared with the subjects not on these medications at the time of death. CONCLUSIONS: These findings are consistent with recent studies measuring CREB levels in this same subject sample, and support current animal and cellular models of antidepressant function.


Subject(s)
Antidepressive Agents/therapeutic use , Bipolar Disorder/therapy , Brain-Derived Neurotrophic Factor/metabolism , Hippocampus/metabolism , Adult , Aged , Bipolar Disorder/drug therapy , Culture Techniques , Cyclic AMP Response Element-Binding Protein/metabolism , Depressive Disorder, Major/metabolism , Electroconvulsive Therapy/methods , Humans , Immunohistochemistry , Middle Aged , Schizophrenia/metabolism
20.
CNS Drug Rev ; 7(1): 1-24, 2001.
Article in English | MEDLINE | ID: mdl-11420570

ABSTRACT

The naphthylamine derivative sertraline is a potent and selective inhibitor of serotonin reuptake into presynaptic terminals. Sertraline has a linear pharmacokinetic profile and a half-life of about 26 h. Its major metabolite, desmethylsertraline does not appear to inhibit serotonin reuptake. Sertraline mildly inhibits the CYP2D6 isoform of the cytochrome P450 system but has little effect on CYP1A2, CYP3A3/4, CYP2C9, or CYP2C19. It is, however, highly protein bound and may alter blood levels of other highly protein bound agents. Sertraline is a widely used serotonin reuptake inhibitor that has been shown to have both antidepressant and antianxiety effects. Many clinical trials have demonstrated its efficacy in depression compared with both placebo and other antidepressant drugs. Its efficacy has also been demonstrated in randomized, controlled trials of patients with obsessive-compulsive disorder, panic disorder, social phobia, and premenstrual dysphoric disorder. In short-term, open-label studies it has appeared efficacious and tolerable in children and adolescents and in the elderly, and data are positive for its use in pregnant or lactating women. Typical side effects include gastrointestinal and central nervous system effects as well as treatment-emergent sexual dysfunction; withdrawal reactions may be associated with abrupt discontinuation of the agent. The safety profile of sertraline in overdose is very favorable. Sertraline's efficacy for both mood and anxiety disorders, relatively weak effect on the cytochrome P450 system, and tolerability profile and safety in overdose are factors that contribute to make it a first-line agent for treatment in both primary and tertiary care settings.


Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Antidepressive Agents, Second-Generation/therapeutic use , Mental Disorders/drug therapy , Selective Serotonin Reuptake Inhibitors/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sertraline/pharmacology , Sertraline/therapeutic use , Aging/psychology , Animals , Antidepressive Agents, Second-Generation/pharmacokinetics , Humans , Mental Disorders/psychology , Selective Serotonin Reuptake Inhibitors/pharmacokinetics , Sertraline/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...